ERBB2 and neoplasm: In a particular study, a bispecific antibody [(HER2)2xCD16] was employed to redirect γδT lymphocytes and NK cells expressing CD16 to HER2, thus enhancing their cytotoxic capabilities against tumor cells that express HER2 (including primary ovarian tumors).